Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Hold" from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received an average rating of "Hold" from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.11.

STRO has been the subject of several research reports. Wedbush cut Sutro Biopharma from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $8.00 to $2.00 in a report on Friday, March 14th. Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective for the company in a research note on Monday. Citizens Jmp cut shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. Bank of America reduced their price target on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a report on Monday, May 19th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 price target on shares of Sutro Biopharma in a research report on Tuesday, April 29th.

Sutro Biopharma Stock Performance

Sutro Biopharma stock traded up $0.00 during trading hours on Monday, hitting $0.79. The company had a trading volume of 719,436 shares, compared to its average volume of 1,113,333. The firm has a market cap of $67.04 million, a P/E ratio of -0.27 and a beta of 1.70. The company has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $1.37. Sutro Biopharma has a 1 year low of $0.52 and a 1 year high of $5.17.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). The firm had revenue of $17.40 million during the quarter, compared to analysts' expectations of $11.61 million. Sutro Biopharma had a negative net margin of 373.66% and a negative return on equity of 347.60%. As a group, equities research analysts anticipate that Sutro Biopharma will post -2.92 EPS for the current year.

Institutional Trading of Sutro Biopharma

Several hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $26,000. Vontobel Holding Ltd. grew its holdings in Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $46,000 after purchasing an additional 10,000 shares during the last quarter. ProShare Advisors LLC grew its holdings in Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after purchasing an additional 11,494 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Sutro Biopharma during the fourth quarter worth $55,000. Finally, Invesco Ltd. lifted its holdings in shares of Sutro Biopharma by 54.2% during the 4th quarter. Invesco Ltd. now owns 38,749 shares of the company's stock valued at $71,000 after purchasing an additional 13,620 shares during the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.